NCT04500847View on ClinicalTrials.gov

Repurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of AD

PHASE1RecruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

December 17, 2021

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
Alzheimer Disease, Early OnsetMild Cognitive ImpairmentModerate Dementia
Interventions
DRUG

Emtriva Capsule

200mg daily oral dose

DRUG

Placebo

200mg daily oral dose

Trial Locations (2)

90048

RECRUITING

Cedars-Sinai Medical Center, Los Angeles

02906

RECRUITING

Memory and Aging Program, Butler Hospital, Providence

Sponsors

Lead Sponsor

Butler Hospital

Collaborators (1)

Brown University
All Listed Sponsors
collaborator

Alzheimer's Association

OTHER

collaborator

Brown University

OTHER

collaborator

The Miriam Hospital

OTHER

collaborator

Cedars Sinai Medical Center, Los Angeles, USA

UNKNOWN

lead

Butler Hospital

OTHER

NCT04500847 - Repurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of AD | Biotech Hunter | Biotech Hunter